PCRC_C51101

A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma

This randomized phase II trial studies how well combination chemotherapy given together with autologous stem cell transplant works compared to combination chemotherapy alone in treating patients with central nervous system B-cell lymphoma

Key Eligibility:

• Diagnosis of primary central nervous system (CNS) diffuse large B-cell lymphoma confirmed by one of the following: Brain biopsy or resection, Cerebrospinal fluid, Vitreous fluid

• No evidence or history of non-Hodgkin lymphoma (NHL) outside of CNS

• No isolated ocular lymphoma or isolated leptomeningeal lymphoma

• At least one measurable, contrast-enhancing brain lesion (greater than or equal to 1 cm in length)

• Karnofsky performance status greater than or equal to 30% ( greater than or equal to 50% for patients ages 60 - 70 years)

• Adequate cardiac function
Phase II
NCT01511562
Oncology
Hematologic
Alison Conlin, M.D.
CALGB
Laurie Delanty

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.